In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Harmony Biosciences trades significantly below a high-confidence fair value of $81.59, indicating substantial upside potential with low Monte Carlo downside risk. Strong financial health scores and robust valuation methods support confidence in growth stability. Volatility is moderate, but the zero downside probability below current price suggests limited near-term valuation risk.